Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 539-546

  Sutter, Iryna ^a,b   Velagapudi, Srividya ^a,b   Othman, Alaa ^a,b,c   Riwanto, Meliana ^b   Manz, Jasmin ^a,b   Rohrer, Lucia ^a,b   Rentsch, Katharina ^a,b,d   Hornemann, Thorsten ^a,b   Landmesser, Ulf ^a,b,e   von Eckardstein, Arnold ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF LÜBECK   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Coronary artery disease; Endothelial cells; HDL; Lipidomics; Plasmalogens; Sphingosine 1 phosphate

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PLASMALOGEN; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; APOA1 PROTEIN, HUMAN; APOLIPOPROTEIN A1; LIPID; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ACUTE CORONARY SYNDROME; ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SERUM; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; CHEMISTRY; CYTOLOGY; DISCRIMINANT ANALYSIS; METABOLISM; MIDDLE AGED; REGRESSION ANALYSIS;

ACUTE CORONARY SYNDROME; ADULT; AGED; APOLIPOPROTEIN A-I; APOPTOSIS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; CORONARY ARTERY DISEASE; DISCRIMINANT ANALYSIS; ENDOTHELIAL CELLS; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; LIPIDS; LIPOPROTEINS, HDL; LYSOPHOSPHATIDYLCHOLINES; LYSOPHOSPHOLIPIDS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PHOSPHATIDYLCHOLINES; PLASMALOGENS; SPHINGOMYELINS; SPHINGOSINE;

EID: 84934995809     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.05.037     Document Type: Article

References (54)

1. Di Angelantonio E., Sarwar N., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. Emerging Risk Factors C.
2. Annema W., von Eckardstein A. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ. J. Off. J. Jpn. Circ. Soc. 2013, 77:2432-2448.
3. Luscher T.F., Landmesser U., von Eckardstein A., Fogelman A.M. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ. Res. 2014, 114:171-182.
4. Riwanto M., Rohrer L., Roschitzki B., et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 2013, 127:891-904.
5. Alwaili K., Bailey D., Awan Z., et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim. Biophys. Acta 2012, 1821:405-415.
6. Vaisar T., Mayer P., Nilsson E., Zhao X.Q., Knopp R., Prazen B.J. HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin. Chim. Acta; Int. J. Clin. Chem. 2010, 411:972-979.
7. Kontush A., Lhomme M., Chapman M.J. Unraveling the complexities of the HDL lipidome. J.Lipid Res. 2013, 54:2950-2963.
8. Davidson W.S., Gillotte K.L., Lund-Katz S., Johnson W.J., Rothblat G.H., Phillips M.C. The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol. J.Biol. Chem. 1995, 270:5882-5890.
9. Rye K.A., Hime N.J., Barter P.J. The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins. J.Biol. Chem. 1996, 271:4243-4250.
10. Zerrad-Saadi A., Therond P., Chantepie S., et al. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arteriosclerosis, Thrombosis, Vasc. Biol. 2009, 29:2169-2175.
11. Baker P.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J.Lipid Res. 2000, 41:1261-1267.
12. Ibdah J.A., Lund-Katz S., Phillips M.C. Molecular packing of high-density and low-density lipoprotein surface lipids and apolipoprotein A-I binding. Biochemistry 1989, 28:1126-1133.
13. Parks J.S., Huggins K.W., Gebre A.K., Burleson E.R. Phosphatidylcholine fluidity and structure affect lecithin:cholesterol acyltransferase activity. J.Lipid Res. 2000, 41:546-553.
14. Subbaiah P.V., Liu M. Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction. J.Biol. Chem. 1993, 268:20156-20163.
15. Piperi C., Kalofoutis C., Papaevaggeliou D., Papapanagiotou A., Lekakis J., Kalofoutis A. The significance of serum HDL phospholipid levels in angiographically defined coronary artery disease. Clin. Biochem. 2004, 37:377-381.
16. Hsia S.L., Duncan R., Schob A.H., et al. Serum levels of high-density lipoprotein phospholipids correlate inversely with severity of angiographically defined coronary artery disease. Atherosclerosis 2000, 152:469-473.
17. Wallner S., Schmitz G. Plasmalogens the neglected regulatory and scavenging lipid species. Chem. Phys. Lipids 2011, 164:573-589.
18. Maeba R., Ueta N. Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers. J.Lipid Res. 2003, 44:164-171.
19. Jurgens G., Fell A., Ledinski G., Chen Q., Paltauf F. Delay of copper-catalyzed oxidation of low density lipoprotein by invitro enrichment with choline or ethanolamine plasmalogens. Chem. Phys. Lipids 1995, 77:25-31.
20. Reiss D., Beyer K., Engelmann B. Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids invitro. Biochem. J. 1997, 323(Pt 3):807-814.
21. Poti F., Simoni M., Nofer J.R. Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P). Cardiovasc. Res. 2014, 103:395-404.
22. Rodriguez C., Gonzalez-Diez M., Badimon L., Martinez-Gonzalez J. Sphingosine-1-phosphate: a bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb. Haemostasis 2009, 101:665-673.
23. Levkau B. Cardiovascular effects of sphingosine-1-phosphate (S1P). Handb. Exp. Pharmacol. 2013, 147-170.
24. Quehenberger O., Armando A.M., Brown A.H., et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J.Lipid Res. 2010, 51:3299-3305.
25. Narayanaswamy P., Shinde S., Sulc R., et al. Lipidomic "deep profiling": an enhanced workflow to reveal new molecular species of signaling lipids. Anal. Chem. 2014, 86:3043-3047.
26. Hornemann T., Penno A., Rutti M.F., et al. The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases. J.Biol. Chem. 2009, 284:26322-26330.
27. Berdeaux O., Juaneda P., Martine L., Cabaret S., Bretillon L., Acar N. Identification and quantification of phosphatidylcholines containing very-long-chain polyunsaturated fatty acid in bovine and human retina using liquid chromatography/tandem mass spectrometry. J.Chromatogr. A 2010, 1217:7738-7748.
28. Laurila P.P., Surakka I., Sarin A.P., et al. Genomic, transcriptomic, and lipidomic profiling highlights the role of inflammation in individuals with low high-density lipoprotein cholesterol. Arteriosclerosis, Thrombosis, Vasc. Biol. 2013, 33:847-857.
29. Yetukuri L., Soderlund S., Koivuniemi A., et al. Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J.Lipid Res. 2010, 51:2341-2351.
30. Pruzanski W., Stefanski E., de Beer F.C., de Beer M.C., Ravandi A., Kuksis A. Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J.Lipid Res. 2000, 41:1035-1047.
31. Graessler J., Schwudke D., Schwarz P.E., Herzog R., Shevchenko A., Bornstein S.R. Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PloS One 2009, 4:e6261.
32. Pietilainen K.H., Sysi-Aho M., Rissanen A., et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects-a monozygotic twin study. PloS One 2007, 2:e218.
33. Meikle P.J., Wong G., Tsorotes D., et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arteriosclerosis, Thrombosis, Vasc. Biol. 2011, 31:2723-2732.
34. Hossain M.S., Ifuku M., Take S., Kawamura J., Miake K., Katafuchi T. Plasmalogens rescue neuronal cell death through an activation of AKT and ERK survival signaling. PloS One 2013, 8:e83508.
35. Brites P., Mooyer P.A., El Mrabet L., Waterham H.R., Wanders R.J. Plasmalogens participate in very-long-chain fatty acid-induced pathology. Brain 2009, 132:482-492.
36. Huang Y., DiDonato J.A., Levison B.S., et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. 2014, 20:193-203.
37. Fisher E.A., Feig J.E., Hewing B., Hazen S.L., Smith J.D. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arteriosclerosis, Thrombosis, Vasc. Biol. 2012, 32:2813-2820.
38. Wang W.Y., Albert C.J., Ford D.A. Alpha-chlorofatty acid accumulates in activated monocytes and causes apoptosis through reactive oxygen species production and endoplasmic reticulum stress. Arteriosclerosis, Thrombosis, Vasc. Biol. 2014, 34:526-532.
39. Wiesner P., Leidl K., Boettcher A., Schmitz G., Liebisch G. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J.Lipid Res. 2009, 50:574-585.
40. Perrin-Cocon L., Diaz O., Carreras M., et al. High-density lipoprotein phospholipids interfere with dendritic cell Th1 functional maturation. Immunobiology 2012, 217:91-99.
41. Zhang W.J., Stocker R., McCall M.R., Forte T.M., Frei B. Lack of inhibitory effect of HDL on TNFalpha-induced adhesion molecule expression in human aortic endothelial cells. Atherosclerosis 2002, 165:241-249.
42. Peshavariya H., Dusting G.J., Di Bartolo B., Rye K.A., Barter P.J., Jiang F. Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free Radic. Res. 2009, 43:772-782.
43. Rye K.A., Duong M., Psaltis M.K., et al. Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling. Biochemistry 2002, 41:12538-12545.
44. Kostara C.E., Papathanasiou A., Psychogios N., et al. NMR-based lipidomic analysis of blood lipoproteins differentiates the progression of coronary heart disease. J. Proteome Res. 2014, 13:2585-2598.
45. Duong M., Psaltis M., Rader D.J., Marchadier D., Barter P.J., Rye K.A. Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids. Biochemistry 2003, 42:13778-13785.
46. Horter M.J., Sondermann S., Reinecke H., et al. Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women. Acta Physiol. Scand. 2002, 176:123-130.
47. Karuna R., Park R., Othman A., et al. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 2011, 219:855-863.
48. Christoffersen C., Obinata H., Kumaraswamy S.B., et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9613-9618.
49. Renkonen O., Hirvisalo E.L. Structure of plasma sphingadienine. J.Lipid Res. 1969, 10:687-693.
50. Panganamala R.V., Geer J.C., Cornwell D.G. Long-chain bases in the sphingolipids of atherosclerotic human aorta. J.Lipid Res. 1969, 10:445-455.
51. Argraves K.M., Sethi A.A., Gazzolo P.J., et al. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011, 10.
52. Sattler K.J., Elbasan S., Keul P., et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res. Cardiol. 2010, 105:821-832.
53. Sattler K., Lehmann I., Graler M., et al. HDL-bound sphingosine 1-phosphate (S1P) predicts the severity of coronary artery atherosclerosis. Cellular physiology and biochemistry. Int. J. Exp. Cell. Physiol., Biochem. Pharmacol. 2014, 34:172-184.
54. Wheelock A.M., Wheelock C.E. Trials and tribulations of 'omics data analysis: assessing quality of SIMCA-based multivariate models using examples from pulmonary medicine. Mol. Biosyst. 2013, 9:2589-2596.